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Abstract
Background: Tenofovir (TDF) is part of the WHO recommended first-line antiretroviral therapy (ART); however, there are
limited data comparing TDF to other nucleoside reverse transcriptase inhibitors in resource-limited-settings. Using a routine
workplace and community-based ART cohort in South Africa, we assessed single drug substitution, HIV RNA suppression,
CD4 count increase, loss-from-care, and mortality between TDF, stavudine (d4T) 30 mg dose, and zidovudine (AZT).
Methods: In a prospective cohort study we included ART naı¨ve patients aged $17 years-old who initiated ART containing
TDF, d4T, or AZT between 2007 and 2009. For analysis of single drug substitutions we used a competing-risks time-to-event
analysis; for loss-from-care, mixed-effect Poisson modeling; for HIV RNA suppression, competing-risks logistic regression; for
CD4 count slope, mixed-effects linear regression; and for mortality, proportional hazards modeling.
Results: Of 6,196 patients, the initial drug was TDF for 665 (11%), d4T for 4,179 (68%), and AZT for 1,352 (22%). During the
first 6 months of ART, the adjusted hazard ratio for a single drug substitution was 2.3 for d4T (95% confidence interval [CI]:
0.27, 19) and 5.2 for AZT (95% CI: 1.1, 23), compared to TDF; whereas, after 6 months, it was 10 (95% CI: 5.8, 18) and 4.4 (95%
CI: 2.5, 7.8) for d4T and AZT, respectively. Virologic suppression was similar by agent; however, CD4 count rise was lowest for
AZT. The adjusted hazard ratio for loss-from-care, when compared to TDF, was 1.5 (95% CI: 1.1, 1.9) for d4T and 1.2 (95% CI:
1.1, 1.4) for AZT. The adjusted hazard ratio for mortality, when compared to TDF, was 2.7 (95% CI: 2.0, 3.5) and 1.4 (95% CI:
1.3, 1.5) and for d4T and AZT, respectively.
Discussion: In routine care, TDF appeared to perform better than either d4T or AZT, most notably with less drug
substitution and mortality than for either other agent.
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Background
Decisions on first-line combination antiretroviral therapy (ART)
regimens for use in resource-limited-settings are made based on
trade-offs regarding cost, need for laboratory monitoring, severity
and frequency of side effects, and effectiveness. Stavudine (d4T)
was initially recommended by the World Health Organization
(WHO) largely due to less need for laboratory monitoring and a
lower price than zidovudine (AZT) [1,2]. As a result of subsequent
accumulated experience with d4T, especially when using 40 mg
dosing for individuals weighing more than 60 kg, the frequency of
severe d4T related side effects became clear. As a result, the WHO
recommended a reduction in d4T dose for patients weighing more
than 60 kg followed thereafter with guidelines recommending
tenofovir disoproxil fumarate (TDF) as part of the preferred
regimen, with AZT as an alternative [3,4].
Despite these changes in WHO recommendations, d4T and
AZT remain widely used due to the higher cost of a month supply
of TDF compared to either d4T or AZT. An additional limiting
factor for TDF uptake is concern related to monitoring patients
receiving TDF for renal toxicity, a potential severe side effect of
TDF. However, in addition to the direct cost of the medication,
other factors need to be considered when selecting an agent for
long-term use, such as the costs of monitoring, need for managing
common toxicities, frequency of the need to change regimens, and
the impact, from a public health standpoint, of loss of patients
from care related to medication side effects. Thus outcome
assessments comparing agents during routine patient care can be
valuable for informing policy regarding ART agent selection.
Two studies set in resource-limited-settings and using routine
program data have compared TDF, d4T (30 mg), and AZT-based
PLOS ONE | www.plosone.org 1 May 2013 | Volume 8 | Issue 5 | e64459
regimens. One was a study from Zambia that compared single
drug substitutions and a composite mortality and loss-from-care
endpoint [5]. The other was a study from Lesotho that assessed
single drug substitutions and all-cause mortality [6]. These two
studies provide important evidence of improved outcomes,
especially fewer switches for toxicity, with the use of TDF when
compared to either d4T or AZT. However, there remains room
for further comparisons of TDF, d4T 30 mg, and AZT, especially
using longer term data and including virologic response, and
robust loss-from-care outcomes. Using a large community and
workplace HIV care program, we have compared the agents TDF,
d4T, and AZT on the following outcomes: single drug substitu-
tions, HIV RNA suppression, CD4 count increase, loss-from-care,
and mortality.
Methods
Ethics Statement
All data were analyzed anonymously and all aspects of this study
were conducted according to the principles expressed in the
Declaration of Helsinki. Human subject research approval for this
study was received from the University of KwaZulu-Natal
Biomedical Research Ethics Committee and the Johns Hopkins
Institutional Review Board.
Population
The study population consisted of HIV-infected patients
enrolled in community or workplace HIV care programs applying
standardized treatment and monitoring approaches and overseen
by a single HIV management organization [7,8]. The workplace
program used a regimen of AZT, lamivudine (3TC), and efavirenz
(EFV) or nevirapine (NVP) until mid-2007, when there was a shift
to TDF, 3TC or emtricitabine (FTC), and EFV or NVP. The
community program used a regimen of d4T, 3TC, and NVP or
EFV until 2009 at which time the regimen shifted to TDF, 3TC,
and NVP or EFV. Patients in the community program prior to
2009 could only be placed on TDF after review of a motivation
from the providing clinician. From June 2007 onwards, a uniform
dose of d4T of 30 mg twice daily was used, without weight-based
dosing, through-out the programs. Patients in the workplace
program were started on ART if they had a CD4 count less than
250 cells/mm3 or a CD4 count less than 350 cells/mm3 with
WHO clinical stage III or any CD4 and WHO clinical stage IV
disease; whereas the community program required a CD4 count
less than 250 cells/mm3 or any CD4 with WHO clinical stage IV
disease. Other patient monitoring and management was similar
between the two programs with similar use of guidelines and
program monitoring and evaluation activities.
For this study, we included patients who were ART naı¨ve at
study entry, $17 years old, initiated ART between June 1, 2007
and June 30, 2009, and were initiated on a regimen of TDF, d4T
(30 mg twice daily), or AZT with 3TC or FTC and either EFV or
NVP. Patients were excluded if they received 40 mg of d4T or if
the dose was not recorded. Entry into observation was defined as
the date of ART initiation. Exit was defined as the earliest date
amongst patient death, time of change of any ART agent, or
24 months elapsed on ART. The study period closed on June 30,
2011, six months prior to the cohort closure, to allow for a
potential 24 months of follow-up with an additional six months for
assignment of appropriate loss to follow-up status for all
participants.
Patient deaths were identified through clinical records and
linkage with the South African National vital status registry for
patients with recorded national identification numbers. We used
inverse probability weighting to adjust for under-ascertainment of
death among patients without recorded national identification
numbers who were lost from care, up weighting individuals lost
from care who had identification numbers and down weighting
those lost from care who did not have identification numbers [9].
To most accurately attribute death to the correct regimen, we
extended the observation time by three months from a change in
an ART agent, as deaths within days of a change in ART agent
would be unlikely to be associated with the new agent but could
plausibly be associated with the prior regimen.
Loss-from-care was defined as any patient whose last clinic or
laboratory record was before closure of the database for the
specific site, in the absence of a recorded treatment stop reason or
death.
Analysis
We compared patient characteristics at ART initiation by initial
NRTI (TDF, d4T, or AZT) using chi-squared or Kruskal-Wallis
testing. We performed time to event analysis for each of single-
agent substitution, loss-from-care and mortality. We used single
agent substitution as a proxy for severe side effects, assessing risk of
substitution using a competing-risks time-to-event analysis, with
death and loss-from-care both considered competing risks, with
robust estimates at site level. In evaluating HIV RNA suppression,
we assessed the proportion with HIV RNA ,400 c/mL at
24 months. We allowed for a window of 3 months earlier or later
(21–27 months) and only included patients with at least one HIV
RNA result during that window. We used the minimum HIV
RNA value if multiple results were available during the window.
We used a random-effects logistic regression for HIV RNA
suppression accounting for the random effect of workplace versus
community HIV program. We also assessed CD4 change over
time on ART up to 24 months on ART. We only included
participants with more than 12 months of follow-up to maintain
consistency with the HIV RNA suppression analysis. We used
mixed effects linear regression to estimate the slope in CD4 count
by NRTI agent and HIV RNA suppression including ART
initiation year, ART clinic setting, and patient, as random effects
in all models (to account for clustering and the longitudinal nature
of the data). We additionally assessed for interactions with NRTI
that could affect CD4 slope. We completed a time to event analysis
for loss-from-care, using a competing risk framework, using death
as the competing risk and using robust estimates at site level. We
used a random effects Poisson model accounting for site-level
effects to calculate incident rates for loss-from-care, adjusted for
site-level differences. For mortality, we calculated hazard ratios
and adjusted hazard ratios using Cox proportional hazard
modeling, controlling for site level effects by using robust estimates
with a fixed effect for program (workplace or community). For
both single drug substitution and loss-from-care competing risk
analyses, we included ART initiation year and ART clinic setting
(workplace or community) to adjust for secular and site level
effects.
In univariable analysis we assessed for associations between the
outcomes and NRTI agent, sex, age, NNRTI agent, WHO
clinical stage at ART initiation, CD4 count at ART initiation,
HIV RNA at ART initiation, and ART initiation year. Except in
the CD4 change analysis, we chose not to use time up-dated data
for CD4 count and HIV RNA as these could potentially be
affected by NRTI agent characteristics (e.g. tolerability, adher-
ence, potency, etc.) and hence could be on the causal pathway
from exposure to outcome.
Because of the considerable imbalance between characteristics
between workplace and community programs, we completed
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sensitivity analyses by repeating all adjusted analyses restricting to
either workplace or community sites. We also explored single-drug
substitutions in a sensitivity analysis restricting to comparisons
between d4T and AZT for the period prior to TDF registration in
South Africa, so as to exclude patients who may have been
switched from another agent to TDF, not because of adverse
events, but because the provider perceived TDF to be superior.
Results
Baseline characteristics
Between June 1, 2007 and June 30, 2009, a total of 8,864 adults
initiated ART, of which 6,196 (70.0%) met inclusion criteria.
There were 2,668 patients excluded because they were not ART
naı¨ve at study entry (n = 2,202), ,17 years old (n = 266), or were
initiated on a regimen other than the allowed regimens (n = 200;
Figure 1). The median age was 40 years (inter-quartile range
[IQR]: 34, 47) and median CD4 count prior to ART was 133
cells/mm3 (IQR: 66, 193; Table 1). Women comprised 52% of
patients. The initial NRTI was TDF for 665 (10.7%), d4T for
4,179 (67.5%), and AZT for 1,352 (21.8%) patients; 3,570 (58%)
received EFV and 2,626 (42%) received NVP. NRTI use was not
uniformly distributed across clinics; patients initiating TDF and
AZT were more likely to be in the workplace program, as were
most of the men and more patients with WHO clinical stage I or II
disease. Patients initiated on d4T were more likely to be women
with lower CD4 counts (Table 1). Total follow-up time was 9,229
person-years and the median follow-up time on ART was
1.9 years (IQR: 1.0–2.0); 1,610 patients died and 500 were lost-
from-care.
Single drug substitutions
Over the first two years of ART, 10 patients had a single drug
substitution from TDF (1.3 per 100 person-years [PYRs]; 95%
confidence interval [CI]: 0.6–2.9), 691 from d4T (8.2 per 100
PYRs; 95% CI: 5.1–13.1), and 95 from AZT (5.1 per 100 PYRs;
95% CI: 3.2–8.5). However, the rate of single drug substitution
varied by time on ART. During the first 6 months of ART, the
rate of single drug substitution was lowest for TDF (2.6 per 100
PYRs; 95% CI: 1.0–6.8) and was similar for d4T (7.4 per 100
PYRs; 95% CI: 4.5–12.0) and AZT (8.7 PYRs; 95% CI: 5.2–14.7).
However, from 6 months onward, the rate was highest for d4T
(5.9 per 100 PYRs; 95% CI: 3.3–10.2) and lower for TDF (0.6 per
100 PYRs; 95% CI: 0.2–1.8) and AZT (3.1 per 100 PYRs; 95%
CI: 1.7–5.6).
In multivariable modeling, the differences in single agent
substitution by time on ART remained (Table 2). During the first
6 months of ART, compared to TDF, the hazard ratio of
substitution for d4T was 2.3 (95% CI: 0.27, 19) and for AZT was
5.2 (95% CI: 1.1, 23); a statistically significant difference between
AZT and TDF. After 6 months of ART, compared to TDF, the
hazard of substitution was 10 (95% CI: 5.8–18) for d4T and 4.4
(95% CI: 2.5, 7.8) for AZT. The change between the first six
months and six to 24 months was significant (p for effect
modification ,0.001). Sex, age, HIV RNA at ART initiation,
WHO clinical stage at ART initiation, and ART initiation year
were all associated with single agent substitution in the multivar-
iable analysis (Table 2). NNRTI agent was associated with hazard
of single-drug substitution in the multivariable analysis, but there
was no interaction between NNRTI agent and NRTI. Nor were
there interactions between NRTI and either sex or age in
predicting single drug substitution.
When restricting to workplace sites for a sensitivity analysis, the
adjusted hazard ratio compared to TDF, was 13.8 (95% CI: 3.5–
55.1) for d4T and 4.7 (95% CI: 1.3–17.0) for AZT during the first
6 months of ART; after 6 months, the hazard ratio was 9.2 (95%
CI: 2.2–38.5) for d4T and 4.7 (95% CI: 1.4–15.8) for AZT. In the
community program, when compared to TDF, during the first
6 months of ART, the adjusted hazard ratio for d4T was 0.9 (95%
CI: 0.3–3.0) and for AZT was 1.5 (95% CI: 0.4–5.1) while after
6 months the adjusted hazard ratio for d4T was 7.3 (95% CI: 1.8–
29.9) and for AZT was 4.2 (95% CI: 1.1–17.8).
We also repeated the analysis restricting to the time period prior
to TDF availability, limiting single drug substitutions to AZT from
d4T or to d4T from AZT. During the first 6 months, the rate of
substitution from d4T was 5.9 per 100 PYRs and from AZT was
5.8 per 100 PYRs. After 6 months the rate from d4T was 4.5 per
100 PYRs and from AZT was 0.5 per 100 PYRs. The hazard ratio
for single agent substitution from d4T (compared to AZT) during
the first 6 months was 1.2 (95% CI: 0.8–2.0), and from d4T
(compared to AZT) from 6–24 months was 7.8 (95% CI: 4.1–
14.8).
Virological suppression at 24 months
The distribution of patients with HIV RNA data at 24 months
was 46% of TDF recipients, 36% of d4T recipients, and 42% of
AZT recipients. Where HIV RNA data were available, HIV RNA
suppression (,400 copies/ml) was achieved in 74% on TDF, 83%
on d4T, and 70% of patients on AZT. In the random-effects
logistic regression model, when compared to TDF, the odds ratio
for virological suppression on d4T was 1.1 (95% CI: 0.7–1.8) and
on AZT was 0.8 (95% CI: 0.5–1.1; Table 3). Factors statistically
associated with viral suppression in the multivariable model
included NNRTI, sex, and CD4 count at ART initiation. There
was no interaction between NRTI and NNRTI.
In a sensitivity analysis of HIV RNA suppression, when
restricting to workplace sites, the adjusted hazard ratio with
TDF as a referent was 1.6 (95% CI: 0.7–3.9) for d4T and 0.9 (95%
CI: 0.6–1.6) for AZT. Restricting to the community program, the
adjusted hazard ratio with TDF as the referent agent was 1.5 (95%
CI: 0.4–5.6) for d4T and was 1.2 (95% CI: 0.3–4.8) for AZT.
CD4 change to 24 months
The distribution of patients with over 12 months of CD4 data
for inclusion in assessing CD4 change was 74% of TDF recipients,
62% of d4T recipients, and 73% of AZT recipients. In mixed
linear regression, with NRTI agent as the only fixed effect, NRTI
agent was significantly associated with CD4 increase with an
annual increase for TDF, d4T, and AZT of 67.0 (95% CI: 61.2,
72.8), 79.2 (95% CI: 76.9, 81.6), and 53.1 (95% CI: 49.2, 56.9)
cells/mm3/year, respectively (p,0.001; Table 4). In adjusted
multivariable analysis, in which we included time updated HIV
RNA suppression and sex as modifiers to the slope along with sex,
age, HIV RNA at ART initiation, and NNRTI as terms in the
intercept, a significant association was maintained. For time points
with HIV RNA suppression, the increase in CD4 count was 83.9
(95% CI: 78.0, 90.0) for TDF, 83.0 (95% CI: 80.0, 86.0) for d4T,
and 73.0 cells/mm3/year (95% CI: 68.0, 76.6) for AZT
(p,0.001).
In a sensitivity analysis, when restricting to workplace sites, we
continued to observe a statistically significant association between
NRTI agent and CD4 slope (p,0.001) with a slope for TDF of
85.3 (95% CI: 78.4, 92.3), for d4T of 90.0 (95% CI: 77.6, 102.3),
and for AZT of 69.0 (95% CI: 62.5, 75.4) cells/mm3/year. In the
community program, the association was no longer statistically
significant (p = 0.3): TDF, 65.2 (95% CI: 42.6, 87.7); d4T, 82.7
(95% CI: 79.3, 86.1); and AZT, 78.4 (71.6, 85.6).
Comparison of Tenofovir, Zidovudine, and Stavudine
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Loss-from-care
During the 24 month follow-up period, the rate for loss-from-
care appeared similar for TDF (9.8 per 100 PYRs; 95% CI: 4.2–
23.0) and AZT (9.5 per 100 PYRs; 95% CI: 4.1–21.7) and was
highest for patients on d4T (11.8 per 100 PYRs; 95% CI: 5.1–
27.5). In the adjusted model, compared to TDF, the hazard ratio
for d4T was 1.5 (95% CI: 1.1–1.9) and for AZT was 1.2 (95% CI:
1.1–1.4; Table 5), a significantly higher loss for d4T and AZT than
TDF.
In the sensitivity analysis when restricting to workplace sites, the
hazard ratio for loss-from-care for d4T was 0.8 (95% CI: 0.4, 1.7)
and for AZT was 1.1 (95% CI: 0.8, 1.5) when compared to TDF.
When restricting to community sites, the hazard ratio for d4T was
2.0 (95% CI: 0.8, 5.0) and for AZT was 1.4 (95% CI: 0.5, 3.6)
when compared to TDF. Thus, when analyzed separately by
workplace and community clinics, NRTI agent was not signifi-
cantly associated with loss-from-care. There were no significant
interactions between loss-from-care and duration on ART, nor
Figure 1. Flow diagram starting with the total number of patients in the ART management cohort, reasons for exclusion, and final
sample for this study.
doi:10.1371/journal.pone.0064459.g001
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were there interactions between NRTI and any of sex, age, or
NNRTI in predicting loss-from-care.
Mortality
The overall adjusted mortality rate for TDF was 9.2 per 100
PYRs (95% CI: 5.9, 14.4), for d4T was 17.8 per 100 PYRs (95%
CI: 11.9, 26.4), and for AZT was 11.1 per 100 PYRs (95% CI: 7.3,
16.7). In adjusted proportional hazards modeling, the hazard ratio
was 2.7 (95% CI: 2.0, 3.6) for d4T and 1.4 (95% CI: 1.3, 1.5) for
AZT when compared to TDF (Table 6).
In a sensitivity analysis, when restricting to workplace sites, the
adjusted hazard ratio for d4T was 1.5 (95% CI: 1.1–2.2) and for
AZT was 1.2 (95% CI: 0.9–1.4) with TDF as a referent. In the
community program the adjusted hazard ratio for d4T was 1.5
(95% CI: 1.3–1.8) and for AZT was 1.0 (95% CI: 0.7–1.5) with
TDF as the referent agent. Thus d4T was associated with higher
mortality in both program types.
Discussion
During the first 24 months of ART, use of TDF as part of a
first-line regimen was associated with lower rates of single drug
substitution than either 30 mg of d4T or AZT. In addition,
mortality appeared lower for TDF and AZT than for d4T.
However, among patients alive and in-care, HIV RNA suppres-
sion was similar and loss-from-care was not consistently different
Table 1. Cohort characteristics at ART initiation by nucleoside reverse transcriptase inhibitor.
Characteristic TDF (n=665) D4T (n =4,179) AZT (n =1,352) p-value
Sex, n (%) ,0.001
Male 527 (79.3) 1,524 (36.5) 920 (68.1)
Female 138 (20.7) 2,655 (63.5) 432 (31.9)
Age in years, n (%) ,0.001
17–29 37 (5.6) 453 (10.8) 96 (7.1)
30–39 253 (38.1) 1,733 (41.5) 449 (33.2)
40–49 204 (30.7) 1,326 (31.7) 462 (34.2)
$50 171 (25.7) 667 (16.0) 345 (25.5)
Initiation Year, n (%) ,0.001
2007 22 (3.3) 1,578 (37.8) 586 (43.3)
2008 327 (49.2) 1,739 (41.6) 503 (37.2)
2009 316 (47.5) 862 (20.6) 263 (19.5)
CD4 count at ART initiation, cells/mm3, n (%) ,0.001
,50 59 (8.9) 660 (15.8) 131 (9.7)
50–99 66 (9.9) 616 (14.7) 166 (12.3)
100–250 240 (36.1) 1,585 (37.9) 544 (40.2)
.250 94 (14.1) 131 (3.1) 157 (11.6)
Missing 206 (31.0) 1,187 (28.4) 354 (26.2)
Median (IQR) 177 (94, 241) 119 (57, 178) 158 (87, 228)
HIV RNA at ART initiation, c/mL, n (%) ,0.001
,1000 4 (0.6) 36 (0.9) 18 (1.3)
1000–50000 159 (23.9) 1,173 (28.1) 461 (34.1)
50001–100000 94 (14.1) 505 (12.1) 170 (12.6)
.100000 211 (31.7) 1,068 (25.6) 298 (22.0)
Missing 197 (29.7) 1,397 (33.3) 405 (30.0)
Log10 Median (IQR) 4.9 (4.5, 5.4) 4.8 (4.4, 5.3) 4.7 (4.2, 5.1)
WHO clinical stage, n (%) ,0.001
I & II 515 (77.4) 1,689 (40.4) 855 (63.2)
III & IV 134 (20.2) 2,183 (52.2) 451 (33.4)
Missing 16 (2.4) 307 (7.4) 46 (3.4)
NNRTI, n (%) ,0.001
EFV 590 (88.7) 1,923 (46.0) 1,057 (78.2)
NVP 75 (11.3) 2,256 (54.0) 295 (21.8)
HIV Program, n (%) ,0.001
Workplace 598 (89.9) 102 (2.4) 809 (59.8)
Community 67 (10.1) 4,077 (97.6) 543 (40.2)
AZT: Zidovudine; d4T: Stavudine; TDF: Tenofovir; IQR: Interquartile Range; NNRTI: non-nucleoside reverse transcriptase inhibitor; EFV: Efavirenz; NVP: Nevirapine.
doi:10.1371/journal.pone.0064459.t001
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by NRTI agent while CD4 count recovery was attenuated for
AZT.
An important strength of our analysis is that our study
population received care in a large routine HIV care program.
Furthermore, we had robust death ascertainment through linkage
to a national vital status registry. However, use of data from
routine service delivery programs also has limitations, including
missing data, the potential for secular trends, and possible
indication bias. For example, we had incomplete data on
suspected adverse reactions. Thus we did not attempt an analysis
based on these data and instead used the proxy of single-drug
substitution to indicate a possible adverse event. Although single-
drug substitutions may have occurred for other reasons, we believe
the majority of these substitutions occurred as a result of suspected
side effects, as the only reason for a single drug NRTI substitution
provided in the treatment guidelines was for side effects. Missing
HIV RNA data may have affected our virologic suppression
analysis; however, we do not suspect a bias in HIV RNA
enumeration by NRTI agent. Another limitation is lack of
adherence data; however, such data are difficult to accurately
and consistently collect in routine care settings.
Most importantly, confounding by indication is an inherent
problem when analyzing cohort data gathered from multiple sites
with changes in care over time. We have attempted to address the
potential of time-effect bias in our results through adjusting for
ART initiation year by either stratification in the Cox proportional
hazards analysis or including it as a random effect in the mixed
effects models. More importantly, there is a substantial risk of bias
due to inclusion of patients from workplace and community
settings as ART regimens and patients differed considerably
between the settings. To address this limitation, we adjusted for
program or clinic in all analyses. In addition, we further assessed
for marked variation in results through sensitivity analyses limited
to either the workplace or community setting. We are reassured by
our findings of overall similar direction of effect when restricting
the analyses; however, the effect size varied. We believe that our
sensitivity analyses help to validate the overall direction of
associations, although the specific effect sizes may be imprecise
and population dependent. The notable discrepancy was with loss-
from-care in which NRTI agent was statistically associated with
loss-from-care in the full analysis but lost association in the
sensitivity analyses. The reason for this remained unclear even
after review of clinic chart abstractions to identify reasons for loss-
from-care that may not have been indicated by routinely
Table 2. Competing-risk regression model for single agent
substitution.
Univariable hazard
ratio
Multivariable hazard
ratio
HR (95% CI)
p-
value
aHR* (95%
CI)
p-
value
NRTI
0–6 months on ART
TDF Referent ,0.001 Referent ,0.001
d4T 3.3 (0.41, 25) 2.3 (0.27, 19)
AZT 5.3 (1.7, 16) 5.2 (1.1, 23)
6–24 months on ART
TDF Referent ,0.001 Referent ,0.001
d4T 14 (7.7, 27) 10 (5.8, 18)
AZT 4.4 (2.8, 7.0) 4.4 (2.5, 7.8)
NNRTI
EFV Referent 0.1 Referent ,0.001
NVP 1.4 (0.9, 2.3) 0.86 (0.82,
0.90)
Sex
Male Referent ,0.001 Referent ,0.001
Female 2.5 (1.7, 3.7) 2.2 (2.1, 2.3)
CD4 count, at ART initiation, cells/mm3
,50 Referent 0.02 Referent ,0.001
50–100 0.9 (0.72, 1.2) 1.0 (0.8, 1.2)
101–250 1.0 (0.76, 1.3) 1.1 (1.0, 1.1)
.250 0.44 (0.22,
0.87)
0.65 (0.50,
0.85)
HIV RNA at ART initiation, c/mL
,50,000 Referent 0.03 Referent 0.2
50,000–
100,000
0.8 (0.7, 0.9) 0.85 (0.70, 1.1)
.100,000 0.9 (0.8, 0.9) 0.92 (0.83, 1.0)
*also adjusted for year of ART initiation, program and site, age and WHO stage.
CI: Confidence Interval; AZT: Zidovudine; d4T: Stavudine; TDF: Tenofovir; NNRTI:
non-nucleoside reverse transcriptase inhibitor; EFV: Efavirenz; NVP: Nevirapine;
HR: Hazard Ratio; aHR: adjusted Hazard Ratio.
doi:10.1371/journal.pone.0064459.t002
Table 3. Random-effects logistic regression model of HIV
RNA suppression at 24 months on antiretroviral therapy.
Univariable odds
ratio
Multivariable odds
ratio
OR (95%
CI)
p-
value
aOR* (95%
CI)
p-
value
NRTI
TDF Referent Referent 0.05
D4T 0.9 (0.6, 1.5) 0.8 1.1 (0.7, 1.8)
AZT 0.7 (0.5, 0.9) 0.02 0.8 (0.5, 1.1)
NNRTI
EFV Referent 0.003 Referent ,0.001
NVP 0.7 (0.6, 0.9) 0.6 (0.4, 0.8)
Sex
Male Referent 0.9 Referent 0.03
Female 1.0 (0.8, 1.3) 1.3 (1.1, 1.8)
CD4 count at ART initiation, cells/mm3
,50 Referent 0.08 Referent 0.03
50–100 1.0 (0.7, 1.5) 1.1 (0.7, 1.6)
101–250 1.3 (0.9, 1.9) 1.4 (1.1, 2.0)
.250 0.9 (0.6, 1.4) 0.9 (0.6, 1.4)
HIV RNA at ART initiation, c/mL
,50,000 Referent ,0.001 Referent 1.0
50,000–
100,000
1.0 (0.7, 1.3) 1.0 (0.7, 1.4)
.100,000 1.1 (0.8, 1.4) 1.1 (0.8, 1.4)
*also adjusted for year of ART initiation, program and site, and age.
aOR: Adjusted Odds Ratio; CI: Confidence Interval; AZT: Zidovudine; d4T:
Stavudine; TDF: Tenofovir; NNRTI: Non-Nucleoside Reverse Transcriptase
Inhibitor; EFV: Efavirenz; NVP: Nevirapine.
doi:10.1371/journal.pone.0064459.t003
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abstracted data. Further studies of loss-from-care, by ART
regimen, from other programs would be of value.
Our study findings were similar, in terms of single drug
substitutions, to a study from Zambia comparing TDF, d4T, and
AZT [5]. In that study, single drug substitutions occurred most
frequently for AZT early after ART initiation; however, over time,
single drug substitutions occurred at a higher rate for d4T.
However, the study from Zambia reported an adjusted hazard
ratio of 1.34, compared to our hazard of 10.6, for substitutions
from d4T. The longer follow-up time in our study may have partly
contributed to the difference, as d4T toxicity increases with time
on ART [10]. A study from Lesotho that had longer follow-up,
reported a hazard ratio of substitution from d4T of 5.4 and from
AZT of 2.3, when compared to TDF [6]. Another possible reason
for a larger effect size in our study is that alternative agents were
more readily available in our South African cohort. This may have
led to a lower threshold for single drug substitutions from AZT or
d4T to TDF than from AZT to d4T or d4T to AZT prior to TDF
availability. The higher rates of substitution that occurred in our
study after TDF became available support this hypothesis. As a
result, it is likely that we have overestimated the frequency of
serious adverse events that truly required drug substitution. It is
notable that in our study, as well as the studies from Zambia and
Lesotho, the d4T regimen used was 30 mg twice daily for all body
weights, yet the rates of substitutions from d4T in response to
Table 4. CD4 count slope based on mixed linear regression model during the first 24 months of ART.
Unadjusted, cells/mm3/year (95%
confidence interval) P for difference
Adjusted*, cells/mm3/year (95%
confidence interval) P for difference
NRTI agent ,0.001 ,0.001
TDF 67.0 (61.2, 72.8) 83.9 (78.0, 90.0)
D4T 79.2 (76.9, 81.6) 83.0 (80.0, 86.0)
AZT 53.1 (49.2, 56.9) 73.0 (68.0, 76.6)
NRTI: nucleoside reverse transcriptase inhibitor; TDF: tenofovir difumarate; AZT: zidovudine.
*slope adjusted for sex and HIV viral suppression; intercept adjusted for sex, age, NNRTI, and baseline HIV RNA.
doi:10.1371/journal.pone.0064459.t004
Table 5. Competing-risk regression model for loss-from-care.
Univariable hazard
ratio
Multivariable
hazard ratio
HR
(95% CI)
p-
value
aHR*
(95% CI)
p-
value
NRTI
TDF Referent ,0.001 Referent 0.008
d4T 1.7 (1.3, 2.2) 1.5 (1.1, 1.9)
AZT 1.1 (0.9, 1.5) 1.2 (1.1, 1.4)
NNRTI
EFV Referent 0.01 Referent 0.06
NVP 0.5 (0.3, 0.9) 0.8 (0.7, 1.0)
Sex
Male Referent 0.004 Referent ,0.001
Female 0.4 (0.2, 0.8) 0.8 (0.7, 0.9)
CD4 at ART initiation, cells/mm3
,50 Referent ,0.001 Referent ,0.001
50–100 1.0 (0.7, 1.4) 1.0 (0.7, 1.4)
101–250 1.3 (0.9, 2.1) 1.1 (0.9, 1.5)
.250 1.7 (1.3, 2.3) 1.2 (1.1, 1.4)
HIV RNA at ART initiation, c/mL
,50,000 Referent ,0.001 Referent ,0.001
50,001–
100,000
1.0 (0.9, 1.1) 1.0 (0.9, 1.2)
.100,000 0.9 (0.8, 1.1) 1.0 (0.8, 1.2)
*also adjusted for program and site, initiation year and age.
CI: Confidence Interval; AZT: Zidovudine; d4T: Stavudine; TDF: Tenofovir; EFV:
Efavirenz; NVP: Nevirapine; HR: Hazard Ratio; aHR: Adjusted Hazard Ratio.
doi:10.1371/journal.pone.0064459.t005
Table 6. Cox-proportional hazard model for mortality.
Univariable hazard
ratio
Multivariable
hazard ratio
HR
(95% CI)
p-
value
aHR*
(95% CI)
p-
value
NRTI
TDF Referent ,0.001 Referent ,0.001
d4T 2.7 (2.0, 3.7) 2.7 (2.0, 3.6)
AZT 1.4 (1.3, 1.5) 1.4 (1.3, 1.5)
NNRTI
EFV Referent 0.6 Referent 0.5
NVP 1.1 (0.8, 1.6) 1.0 (0.9, 1.0)
Sex
Male Referent 0.4 Referent 0.8
Female 1.2 (0.7, 1.9) 1.0 (0.9, 1.1)
CD4 count at ART initiation, cells/mm3
,50 Referent ,0.001 Referent ,0.001
50–100 0.9 (0.7, 1.0) 0.9 (0.8, 1.0)
101–250 0.6 (0.5, 0.7) 0.7 (0.6, 0.7)
.250 0.4 (0.2, 0.9) 0.6 (0.4, 0.9)
HIV RNA at ART initiation, c/mL
,50,000 Referent ,0.001 Referent ,0.001
50,000–
100,000
1.3 (1.1, 1.4) 1.2 (1.0, 1.3)
.100,000 1.4 (1.3, 1.5) 1.2 (1.2, 1.3)
*also adjusted for year of ART initiation, program, site, age and WHO stage.
HR: Hazard Ratio; aHR: Adjusted Hazard Ratio; CI: Confidence Interval; AZT:
Zidovudine; d4T: Stavudine; TDF: Tenofovir; NNRTI: non-nucleoside reverse
transcriptase inhibitor; EFV: Efavirenz; NVP: Nevirapine.
doi:10.1371/journal.pone.0064459.t006
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adverse events were still high. The high rate of side effects from
30 mg of d4T has also been reported from a comparison of 30 and
40 mg dosing of d4T [11].
Neither the Zambian nor the Lesotho studies identified
differences in loss-from-care by regimen. Drug tolerability is a
reported reason for discontinuation of care [12], how important a
factor it is in any of these environments is unclear.
Our mortality findings were also similar to the Zambian and
Lesotho studies in which d4T was associated with an increased
mortality hazard. Both AZT and d4T were associated with a
higher mortality in the Lesotho study [6]. Of note, our total overall
mortality was high. This finding may be related to increased
ascertainment through the use of linkage to a vital statistics register
[9,13–16].
We did not observe a difference in HIV RNA suppression by
NRTI at 24 months. The comparable studies from Zambia and
Lesotho did not assess this outcome as HIV RNA enumeration
was not part of routine ART care in those countries. This finding
suggests that among patients remaining in-care and attending
clinic sessions, agent efficacy was similar. In addition, there was no
evidence that the worse outcomes with d4T were mediated
through a lower rate of HIV RNA suppression (or adherence as
estimated by HIV RNA suppression).
Although HIV RNA suppression did not differ by NRTI, CD4
count slope was slightly less for patients receiving AZT. This is
consistent with prior AZT experience, although the absolute
difference in slope is less pronounced than reported from several
clinical trials in which the differences were approximately 30 cells/
mm3 [17–20]. The clinical implications of a slightly slower CD4
count rise with AZT are unclear.
In our cohort, TDF appeared to outperform d4T at the 30 mg
dosing and AZT in terms of need for drug substitution and all-
cause mortality. From a public health standpoint, fewer drug
substitutions may be important for program success and control-
ling costs. We believe that our results add to the data supporting
the public health use of TDF as part of a first-line regimen, as
recommended by the WHO. Our findings also suggest that, even
at the current lower dose of d4T, the agent continues to have
adverse effects leading to single-drug substitutions and may be
contributing to increased losses from care and mortality. Longer-
term evaluations of these regimens are needed.
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